Holen Sie sich die Stockscreener-App
3.41
1.79%
0.06
Aptose Biosciences Inc Aktie (APTO) Neueste Nachrichten
Aptose Biosciences, Inc. to Host Earnings Call - ACCESS Newswire
Aptose Biosciences (NASDAQ:APTO) Earns Sell Rating from Analysts at StockNews.com - Defense World
Aptose Biosciences (NASDAQ:APTO) Upgraded at Alliance Global Partners - Defense World
Aptose Biosciences (TSE:APS) Upgraded at Alliance Global Partners - Defense World
Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Update - MarketBeat
Investor Network: Aptose Biosciences Inc. to Host Earnings Call - ACCESS Newswire
Aptose Biosciences Inc. to Host Earnings Call - ACCESS Newswire
Aptose Biosciences initiated with a Speculative Buy at Alliance Global Partners - TipRanks
Aptose's leukemia drug cleared to double clinical trial dose - MSN
Aptose Biosciences Inc (NASDAQ: APTO) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com - Defense World
Aptose Biosciences finalizes reverse stock split - Investing.com India
Aptose Biosciences Stock to Reverse Split on Wednesday, February 26th (NASDAQ:APTO) - Defense World
Aptose Biosciences finalizes reverse stock split By Investing.com - Investing.com Canada
Aptose Announces Positive Clinical Safety Review Committee - GlobeNewswire
Aptose advances AML treatment with higher dose in trial By Investing.com - Investing.com Nigeria
Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday? - Benzinga
Aptose Biosciences Moves Forward With TUS Escalation In TUSCANY Trial After Positive Data - Nasdaq
Aptose's leukemia drug cleared to double clinical trial dose | 2025-02-20 | Investing News - Stockhouse Publishing
Aptose advances AML treatment with higher dose in trial - Investing.com India
Aptose Biosciences Brief: This Amid "Complete Responses and Favorable Safety in First Cohort" - Marketscreener.com
Aptose Biosciences Brief: Announcing "Positive" Clinical Safety Review Committee Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib - Marketscreener.com
Breakthrough in AML Treatment? Aptose's Triple Drug Therapy Achieves Complete Responses in First Trial Cohort - StockTitan
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga India
US Stocks Likely To Open Lower Following Fresh Records From Previous Session: Expert Says, 'Don't Be Scared Of New Highs' - Benzinga
Aptose Biosciences plans reverse stock split to meet Nasdaq rules By Investing.com - Investing.com Canada
Aptose Biosciences approves 1-for-30 reverse share split to restore Nasdaq compliance - MSN
Aptose Biosciences Announces Reverse Share Split - TipRanks
Aptose Biosciences plans reverse stock split to meet Nasdaq rules - Investing.com India
Aptose Biosciences Inc. Announces Reverse Share Split to Enhance Compliance with Nasdaq Listing Requirements - Nasdaq
Aptose Announces Reverse Share Split - GlobeNewswire
Aptose Takes Bold Action: 30-to-1 Share Consolidation to Secure Nasdaq Future - StockTitan
US Stocks Likely To Open Higher Amid Ukraine Peace Talk Hopes As Russian, American Officials Meet - Benzinga India
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket - Benzinga India
Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com - Defense World
Aptose Biosciences announces resale of 12.03M shares by Keystone Capital Partners - MSN
Aptose Biosciences secures $25 million equity facility - MSN
Aptose Biosciences (NASDAQ:APTO) Earns “Buy” Rating from HC Wainwright - Defense World
Aptose Biosciences Inc. (NASDAQ: APTO) Issues Press Release on February 12, 2025 - Defense World
Aptose Biosciences Secures $25M Share Purchase Agreement - TipRanks
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility - GlobeNewswire
Aptose Biosciences secures $25 million equity facility By Investing.com - Investing.com Canada
Aptose Biosciences Enters $25 Million Common Share Purchase Agreement to Support AML Therapy Development - Nasdaq
2.14%
2.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):